Search - tctmd.com

Displaying 1 - 20 of 167

Sort: Relevancy | Date

News Daily News

Andexanet Alfa Pulled From US Market

Todd Neale

December 22, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

L.A. McKeown

May 16, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2025

Caitlin E. Cox

April 30, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

L.A. McKeown

February 14, 2025

News Opinion CV Team Dispatch

February 2025 Dispatch for the CV Team

L.A. McKeown

February 01, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

L.A. McKeown

August 26, 2024

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

L.A. McKeown

August 19, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Michael O'Riordan

July 09, 2024

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

L.A. McKeown

May 17, 2024

News Daily News

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

L.A. McKeown

April 18, 2024

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

Todd Neale

February 15, 2024

News Daily News

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

Todd Neale

February 02, 2024

News Daily News

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

Shelley Wood

January 17, 2024

Advertisement

Andexanet Alfa Pulled From US Market

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

What’s Going to Be Hot at AHA 2025?

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

TCTMD’s Top 10 Most Popular Stories for April 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

What’s Going to Be Hot at ACC 2025?

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

February 2025 Dispatch for the CV Team

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Scientific Statement Reviews Current Antithrombotic Options in PAD

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content